Parnaparin

DB09260ApprovedSmall molecule

Parnaparin is a low molecular weight heparin (LMWH) used to prevent blood clots, specifically deep vein thrombosis.

Mechanism
Curator reviewed
Primary indication
Used in the prevention and treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism) and in the treatment of myocardial infarction.Curator reviewed · 3 structured indications
Also known as
Parnaparin sodium

Resolves to

Compound
UNIIM316WT19D8CAS9005-49-6
Clinical / RWD
RxNorm69528ATCB01AB07
Targets
P01008SERPINC1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
865Drug interactionsStructured to mechanism, not free text
Sign in
3Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
16ContraindicationsEach with its own population and attribute set
Sign in
26Marketed productsAcross 3 countries and 3 labellers
Sign in
1ATC codeIncluding every combination product, plus 11 drug categories
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Parnaparin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In